Neither a fizzled merger nor worries over clinical trial supply of its osteoporosis drug Preos kept NPS Pharmaceuticals Inc. from forging ahead with the pivotal Phase III study and meeting the primary endpoint of reducing vertebral fractures in the top-line data analysis. (BioWorld Today) Read More
